Integra LifeSciences (IART) shares fell 11% in Friday's premarket session after it reported preliminary Q3 adjusted earnings of $0.55 to $0.59 per diluted share.
The company expects revenue for the quarter ended Sept. 30 of $410 million to $412 million.
Analysts surveyed by FactSet expect $416.3 million.
For full-year 2026, the company expects adjusted EPS of $2.30 to $2.40 on revenue of $1.63 billion to $1.65 billion, down from previous guidance of $2.40 to $2.50 on revenue of $1.65 billion to $1.70 billion.
Analysts surveyed by FactSet expect adjusted EPS of $2.45 and revenue of $1.67 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.